Cellectar Biosciences (CLRB): Can Shares Reach the $11.50 Analyst Target (+827% Upside)?

Key Takeaways

• The central $11.50 target represents the arithmetic mean of four verified analyst price targets: Maxim Group ($10), Ladenburg Thalmann ($10), Roth MKM ($11) and Brookline Capital Markets ($15).
• The four targets span a wide $10 to $15 range, reflecting genuine disagreement about the company's clinical and regulatory prospects.
• With shares near $1.24, reaching $11.50 would require a gain of roughly 827%, an extraordinarily large move even by biotech standards.
• The strongest supporting factor is a late-stage clinical catalyst: a confirmatory Phase 3 program for iopofosine I-131 in Waldenstrom's macroglobulinemia.
• The biggest risks are pre-revenue status, persistent cash burn, potential dilution, and the possibility that the targets have simply not caught up to the stock's decline.
• For additional context on this ticker's Major News and Today's Price Move, its Forecast, and its Earnings, explore the dedicated pages.
• Interested readers can also explore Trending AI Robots for data-driven trading ideas across thousands of tickers.

Analyst Price Targets and Consensus View

Four current analyst price targets were reviewed to calculate the central target. Maxim Group and Ladenburg Thalmann each maintain a $10 target with Buy ratings, both most recently updated on August 14, 2026. Roth MKM carries an $11 target (reiterated at Buy in May 2026 after being lowered from $14). Brookline Capital Markets initiated coverage with a $15 target in July 2026. The arithmetic mean of these four figures is $11.50, matching the $11.50 one-year target estimate reported independently by Yahoo Finance and Barron's. The $10 to $15 range is unusually wide relative to the mean, and the reasoning differs meaningfully. The higher targets emphasize the potential market opportunity for iopofosine I-131 in relapsed or refractory Waldenstrom's macroglobulinemia, a rare B-cell malignancy, while the more cautious figures weigh the execution and financing risk of a pre-revenue company. Notably, several data providers flag that the stock has fallen sharply over the past year and that analyst price targets may not yet have fully adjusted. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

With shares around $1.24, the gap to the $11.50 central target implies upside of about 827%, which is a very large move by any standard. The stock's 52-week range of $1.11 to $4.70 underscores how far it has retreated, and the company's market capitalization of roughly $11.7 million sits below the approximately $34 million in cash it reported in its most recent filing. The path toward the target would depend almost entirely on clinical and regulatory outcomes rather than current fundamentals. CLRB remains pre-revenue, reporting a net loss of about $22.3 million over the trailing twelve months and diluted EPS of approximately -$3.46. A re-rating of this magnitude would likely require positive confirmatory data and a credible route toward regulatory approval and commercialization.

What Could Support a Move Toward the Target

The central investment thesis rests on the confirmatory Phase 3 program for iopofosine I-131, which previously received Breakthrough Therapy Designation in Waldenstrom's macroglobulinemia. If the study demonstrates durable response rates consistent with earlier Phase 2 results, it could validate a differentiation argument in an underserved hematologic cancer setting and re-establish a regulatory path toward accelerated approval. The PDC platform itself provides additional optionality, with earlier-stage programs such as CLR 121125 and CLR 225, along with collaborations with partners including Orano Med and LegoChem Bio. A relatively modest enterprise value relative to reported cash also means any positive clinical catalyst could have an outsized effect on a thinly traded micro-cap stock.

What Could Prevent the Target From Being Reached

The obstacles are substantial. As a pre-commercial company, Cellectar generates no recurring product revenue, and continued spending on the confirmatory study will consume liquidity. The financing tied to clinical and warrant-related milestones is not assured, and the associated warrant structure creates the risk of meaningful dilution for existing shareholders. The stock's roughly 61% decline over the past year suggests the market has already discounted significant clinical and regulatory risk. If confirmatory data disappoint, or if the accelerated-approval pathway stalls, the shares could remain under pressure. In that scenario, analyst targets set in mid-2026 may prove optimistic relative to the prevailing stock price.

Technical Levels and Market Structure

From a technical standpoint, the shares are trading in the lower portion of a long-term downtrend. The 52-week low near $1.11 represents a key support level, while the $1.28 to $1.31 area has served as recent resistance. More meaningful recovery levels sit well above, with the prior 52-week high of $4.70 marking the most prominent overhead zone. Given the micro-cap float and average volume below 100,000 shares on many sessions, price swings can be pronounced and driven by single news events rather than broad market structure. From what I see, monitoring these levels closely makes sense given the event-driven nature of the name.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though the timing of individual targets varies here — several were set months ago and may not yet reflect the latest share price. Investors should monitor the confirmatory Phase 3 trial's enrollment and interim data readouts, any regulatory interactions with the FDA, financing announcements and dilution, and quarterly cash-burn figures. Analyst revisions following these events will be especially informative, as they will indicate whether the existing price targets remain credible.

AI Daily Buy/Sell Signals

In my research process I often turn to Tickeron's AI Daily Buy/Sell Signals to track volatile names like this one. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions and technical behavior. For a news-sensitive micro-cap such as CLRB, it offers an efficient way to stay on top of potential changes without constant manual review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume